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Objective: The G-protein coupled receptor family C group 6 member A (GPRC6A) is activated by
proteinogenic amino acids and may sense amino acids in the gastrointestinal tract and the brain. The
study investigated whether GPRC6A was necessary for the effects of low- and high-protein diets on
body weight and food intake in mice.
Methods: The role of GPRC6A in mediating the effects of a low-protein diet on body weight was investi-
gated in GPRC6a knockout (GPRC6a-KO) and wild-type (WT) mice fed a control diet (18% protein) or a
low-protein diet (6% protein) for 9 days. The role of GPRC6A in mediating the effects of a high-protein
diet on body weight was investigated in GPRC6a-KO and WT mice fed a control diet (18% protein) or a
high-protein diet (50% protein) for 5 weeks.
Results: A high-protein diet reduced body weight gain and food intake compared with a control diet in
both WT and GPRC6a-KO mice. A low-protein diet decreased body weight gain in GPRC6a-KO mice.
Conclusions: GPRC6A was not necessary for the effects of a low- or high-protein diet on body weight
and likely does not play a role in protein-induced satiety.
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Introduction
Protein has a powerful satiating effect that is greater than that of carbo-
hydrate or fat (1). High-protein diets reduce food intake, facilitate
weight loss, and improve body composition in both humans and animal
models (2,3), but they are difficult to adhere to. Rodents have been
shown to avoid low-protein diets, resulting in reduced body weight
when ad libitum fed such a diet (4). In contrast, feeding rodents diets
moderately low in protein can cause initial periods of reduced food
intake, followed by a subsequent increase in food intake and body fat
which is thought to reflect a drive to increase protein intake (5,6). Diets
containing disproportionate amounts of specific amino acids can also
result in changes in food intake (7). However, although several possi-
bilities have been proposed (8), the precise mechanisms by which pro-
tein intake is sensed in order to modulate appetite remain to be eluci-
dated (9). Exploiting the systems by which protein suppresses appetite
may be a viable approach to the treatment of obesity (2).
The digestion of proteins results in the production of small peptides
and amino acids in the lumen of the gastrointestinal tract. Recent
evidence suggests that L-amino acids may be sensed by a group of
promiscuous G-protein coupled receptors which include the T1R1/
T1R3 heterodimer, the calcium sensing receptor (CaSR), and the
G-protein coupled receptor family C group 6 member A (GPRC6A).
Both human and mouse GPRC6A orthologs are activated by basic
L-amino acids, including arginine, lysine, ornithine, and several ali-
phatic amino acids (10). Arginine and lysine have been demon-
strated to reduce appetite in rodents, though the mechanisms by
which they mediate these effects are unclear (11). GPRC6A is
expressed in a wide range of tissues (12), suggesting it may serve a
diverse range of physiological functions, and there is interest in
GPRC6A as a potential novel target in therapeutic areas such as
metabolism, obesity, and endocrine function (13).
GPRC6a knockout (GPRC6a-KO) mouse models have previously
been used to investigate the physiological roles of GPRC6A. Pi et al.
generated the first global GPRC6a-KO mice by targeted deletion of
exon II (GPRC6aexon 2(2/2)) (14). Exon II encodes for a minor part of
the venus fly trap domain of the receptor which contains an orthosteric
binding site for endogenous ligands. This mouse is reported to have
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multiple physiological abnormalities, including disrupted bone metab-
olism, feminization of the male mice, adiposity, and glucose intoler-
ance. Wellendorph et al. subsequently described another GPRC6a-KO
mouse, in which exon VI, containing the entire 7 transmembrane and
C-terminal region of the receptor, was disrupted (GPRC6aexon 6(2/2))
(15). In contrast to the GPRC6aexon 2(2/2) model, the GPRC6aexon 6(2/
2) model has been reported to have a normal bone phenotype and nor-
mal glucose tolerance (15,16).
GPRC6aexon 6(2/2) mice with ad libitum access to standard chow
diet have normal food intake and body weight progression (15), but
GPRC6aexon 2(2/2) mice on the same diet have increased
adiposity (14). However, a recent study demonstrated that
GPRC6aexon 6(2/2) mice show a similar phenotype when placed on
a high-fat diet, becoming hyperphagic and exhibiting increased body
weight and impaired glucose homeostasis (17). Therefore, despite
the differences between the knockout models, evidence suggests a
role for GPRC6A in energy homeostasis and metabolism.
GPRC6A expression has been reported in the alimentary system, spe-
cifically within gastrin expressing cells of the stomach (18), and in
pancreatic tissue, and it has also been detected in the mouse TC-6 pan-
creatic b-cell line (19). It has been suggested that GPRC6A mediates
the effects of the amino acid L-arginine on insulin release from mouse
pancreatic islet (20), though this has not been found by all groups
(16). In addition, the bone-derived hormone osteocalcin has been
reported to enhance GPRC6A activity (21), though in a recent study
another group were not able to demonstrate osteocalcin agonism at
GPRC6A (22). Osteocalcin promotes beta cell proliferation and can
stimulate insulin release directly and indirectly via the release of
glucagon-like peptide-1 (GLP-1) from enteroendocrine cells, and these
effects are thought to be mediated by GPRC6A, as demonstrated using
an exon II pancreas-specific GPRC6a-KO mouse model (23). GLP-1
expressing L cells in the intestine sense nutrients in order to regulate
glucose and energy homeostasis (24). This data is thus in accord with
suggestions that GPRC6A acts as a nutrient sensor in the digestive sys-
tem (25), though the relative expression of GPRC6A in different
regions of the gut has not been reported. It has been proposed that
GPRC6A may sense amino acids in order to detect protein ingestion
and modulate food intake accordingly and thus may be a useful target
for pharmacological agents to treat obesity (13,26). However, the
physiological role of GPRC6A in mediating the response to altered
protein intake is unknown. We investigated the acute and chronic
effects of altered dietary protein concentrations on food intake and
body weight in wild-type (WT) and GPRC6a-KO mice to assess the
putative role played by GPRC6A in modulating protein-induced
changes in energy homeostasis.
Methods
Animals
The GPRC6a-KO model used in our studies was obtained from the
Knockout Mouse Project (KOMP) (27). The C57BL/6NTac inbred
mouse was used as the genetic background for developing the
GPRC6a-KO congenic strain (Taconic, USA). The deleted region con-
sisted of 16,596 base pairs, which completely covers the GPRC6a
locus. GPRC6a-targeted heterozygous C57B1/6N mice were bred to
produce homozygous GPRC6a-KO animals and WT littermate con-
trols. All experiments were conducted in 6-8 week old male mice indi-
vidually housed on a 12 h light: 12 h darkness cycle under controlled
temperature and humidity. We found no difference in basal glucose
levels or in the response to an intraperitoneal glucose tolerance test
(IPGTT) between GPRC6a-KO animals and WT controls (Supporting
Information Figure S1). All animals were weight-matched prior to the
start of the chronic studies. Animal procedures were approved under
the UK Home Office Animals (Scientific Procedures) Act 1986.
GPRC6a expression in the gastrointestinal tract
A cohort of WT and GPRC6a-KO mice fed RM1 standard chow
diet (RM1 diet; Special Diet Services, Witham, Essex, UK) were
fasted overnight to avoid any effects of acute food intake on gene
expression. Mice were then decapitated and stomach, duodenum,
jejunum, ileum, and colon rapidly removed, snap frozen, and stored
at 280C for RNA extraction and qPCR. Total RNA was extracted
from gastrointestinal tissues using TRI reagent (Sigma-Aldrich,
Poole, UK) in accordance with the manufacturer’s instructions.
Reverse transcription was carried out using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies, Paisley, UK)
according to the manufacturer’s instructions. Real-time quantitative
PCR analysis was performed using TaqMan Gene Expression Assays
and TaqMan Universal PCR Master Mix (Life Technologies, Pais-
ley, UK) using the ABI Prism 7900 Sequence Detection System
according to the protocols provided by the manufacturer (Life Tech-
nologies, Paisley, UK). The relative mRNA transcript levels were
calculated according to the 2–DCT method, with DCT being the dif-
ference in cycle threshold values between the GPRC6a mRNA
(Mm00467618_m1), T1R1 mRNA (Mm00473433_m1), T1R3
mRNA (Mm00473459_g1) or CaSR mRNA (mCG130161), and the
hypoxanthine phosphoribosyltransferase 1 (HPRT1) mRNA
(m00446968_m1) internal control. GPRC6a expression was also
measured using the same methodology in tissues from WT mice
from the chronic high protein intake study described below. For
these studies, expression analysis was carried out at the end of the
5-week-high-protein diet feeding. The animals were fasted overnight
prior to the cull and tissue collected as described above.
Acute and chronic effects of high protein intake
in GPRC6a-KO mice
The effects of an acute protein load on food intake were compared
in WT and GPRC6a-KO mice in a randomised paired cross over
study. Animals were orally gavaged with water or cooked chicken
breast (Supporting Information Table S1B) homogenised in water
(2 g/kg) during the early light phase following an overnight 16 h
fast. The chicken breast was pressure cooked, the fat removed by
centrifugation, and the chicken then homogenised in water according
to a previously published method (26). Food intake was measured at
1, 2, 4, 8, and 24 h postadministration.
To examine the role of GPRC6A in sensing chronically elevated
protein intake, WT control and GPRC6a-KO mice were given ad
libitum access to an 18% protein control diet or a 50% high-protein
diet (HP) (Supporting Information Table S1A) (Harlan Teklad,
Oxfordshire, UK). Diets were isocaloric and matched for fat content
(Supporting Information Table S1A). Body weight and food weight
were measured at least three times a week for 5 weeks. Animals
were then fasted overnight, culled and tissues collected from differ-
ent regions of the gastrointestinal tract for RNA extraction.
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Effects of a low-protein diet
in GPRC6a-KO mice
To investigate the potential role of GPRC6A in mediating the
response to low protein intake, WT control, and GPRC6a-KO mice
were given ad libitum access to an 18% protein control diet (Sup-
porting Information Table S1A) or a 6% low protein diet (LP) (Sup-
porting Information Table S1A) (Harlan Teklad, Oxfordshire, UK).
Diets were isocaloric and matched for fat content (Supporting Infor-
mation Table S1A). Body weight and food intake were measured on
days 1-5 and 8-9.
Statistical analysis
All values are mean6SEM unless otherwise stated. Differences in
cumulative food intake and body weight data through time were
compared across experimental groups using generalized estimating
equation curve analysis (Stata 9.1; Statacorp, College Station, TX).
All other comparisons were made using either one way ANOVA fol-
lowed by Tukey’s test post hoc comparisons or multiple t test (Prism
6.03, GraphPad Software Inc). P< 0.05 was considered significant.
Results
GPRC6a expression in the gastrointestinal tract
We examined the expression of GPRC6a in different levels of the
gastrointestinal tract in mice. GPRC6a expression was detected in
all regions of the gastrointestinal tract investigated, with the highest
expression observed in the jejunum and colon (Figure 1A).
In addition to GPRC6A, CaSR and T1R1-T1R3 receptor complexes
have been suggested to mediate amino acid sensing in the gut (28). It
is therefore possible that the expression of CaSR and/or T1R1-T1R3
may be upregulated to compensate for the absence of GPRC6A
expression. In order to investigate whether deletion of GPRC6A alters
the expression of these receptors, we measured their expression in
both WT and GPRC6a-KO mice. There were no significant differen-
ces in the expression of T1R1, T1R3, or CaSR in the regions of the
gastrointestinal tract examined between WT or GPRC6a-KO mice,
suggesting that expression of these receptors is not altered in the gut to
compensate for the loss of GPRC6A (Figure 1B).
Acute and chronic effects of high protein intake
in GPRC6a-KO mice
To investigate the role of GPRC6A in mediating the effects of high
protein intake, WT and GPRC6a-KO mice were orally administered
with a vehicle control or a high protein load. Acute oral administra-
tion of a protein load significantly reduced food intake in both WT
(0.6946 0.027 g control vs. 0.4966 0.089 g high protein load) and
GPRC6a-KO 0.6506 0.032 g control vs. 0.370g 0.0576 high protein
load) mice in the 0-1 h period following administration (P< 0.05)
(Figure 2). This was an acute affect, with no significant suppression
of food intake observed in WTs or GPRC6a-KO animals in subse-
quent time intervals monitored up to 24 h following administration
(data not shown).
To determine whether GPRC6A is necessary for the chronic sup-
pression of food intake and body weight driven by high protein
(29), we placed WT and GPRC6a-KO mice on either a high-protein
Figure 1 (A) Relative expression of GPRC6a mRNA in different regions of the gas-
trointestinal tract of overnight fasted male WT mice fed a control diet. Data is pre-
sented as mean6SEM. ***P< 0.001 vs. stomach, duodenumn and ileum.
#P<0.01 vs. colon. †P< 0.001 vs. stomach, duodenum, and ileum. n57. (B) Rel-
ative expression of T1R1, T1R3, and CaSR mRNA in different regions of the gas-
trointestinal tract in male WT and GPRC6a-KO mice fed a control diet. The
expression levels are relative to WT mice. Data is presented as mean6SEM.
n5 4–6 per group.
Figure 2 The effect of oral administration of a protein load (HP) on acute 0–1 h
food intake in the early light phase following an overnight fast in GPRC6a-KO mice.
Data is presented as mean6SEM. *P< 0.05, HP vs. control in WT mice.
$P< 0.05, HP vs. control in GPRC6a-KO mice. n54–5 per group.
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or a control diet for 5 weeks. There was no significant difference
between the absolute body weights of animals between diet or geno-
type groups (day 0: 21.686 0.90 g WT control vs. 22.416 0.87 g
WT-HP, 21.056 1.18 g GPRC6a-KO-control vs. 23.306 1.37 g
GPRC6a-KO-HP, P> 0.05; day 35: 31.966 0.98 g WT control vs.
30.746 0.95 g WT-HP, 30.916 1.50 g GPRC6a-KO-control vs.
31.356 1.35 g GPRC6a-KO-HP, P> 0.05). However, ad libitum
access to a high-protein diet significantly reduced body weight gain
(Figure 3A,B) and food intake (Figure 3C) in both GPRC6a-KO
mice and age-matched WT controls (P< 0.05).
Expression levels of the receptors involved in the physiological
response to ingested protein might be expected to adapt to a chronic
high-protein diet. To investigate whether a high-protein-diet modu-
lates the expression of GPRC6A in the gastrointestinal tract, we
measured GPRC6a mRNA expression in different regions of the
gastrointestinal tract of WT mice exposed to a control or a high-pro-
tein diet for 5 weeks. There was no significant difference in
GPRC6a expression in WT mice exposed to a high-protein diet
compared to those fed a control diet in any of the regions of the
gastrointestinal tract examined (Figure 4).
Effects of a low-protein diet
in GPRC6a-KO mice
In order to investigate the potential role of GPRC6A in mediating
the effects of a low-protein diet in mice, we placed both WT and
GPRC6a-KO mice on either low-protein or control diets for 9 days.
It has been shown that mice initially lose weight when placed on a
low-protein diet due to reduced food intake (30), though there is
often a subsequent increase in food intake (5,6). There was no sig-
nificant difference between the absolute body weights of animals
between diet or genotype groups (day 0: 21.656 1.98 g WT control
vs. 22.666 1.32 g WT-LP, 22.326 0.98 g GPRC6a-KO-control vs.
22.276 1.07 g GPRC6a-KO-LP, P> 0.05; day 9: 24.026 1.44 g
WT-control vs. 24.356 0.70 g WT-LP, 24.786 1.00 g GPRC6a-
KO-control vs. 24.506 0.81 g GPRC6a-KO-LP, P> 0.05). How-
ever, GPRC6a-KO mice fed a low-protein diet displayed reduced
body weight gain compared to GPRC6a-KO mice on a control diet.
Although WT animals fed a low-protein diet had lower average
body weight gain, this effect was not significant (Figure 5A,B).
Both WT and GPRC6a-KO mice fed a low-protein diet had a lower
average food intake compared to those fed an 18% protein diet, but
these effects did not achieve statistical significance (Figure 5C).
These observations suggest that GPRC6A is not necessary for the
effects of a low-protein diet on body weight and food intake.
Figure 3 The effect of a high-protein (HP) diet on (A, B) body weight gain and (C)
cumulative food take in WT and GPRC6a-KO mice. Data is presented as mean-
6SEM. (A) and (C): *P< 0.05, HP diet vs. control diet in WT mice. $P< 0.05, HP
diet vs. control diet in GPRC6A mice determined using generalized estimating
equation curve analysis for the entire 5 weeks. (B): *P< 0.05, HP diet vs. control
diet in WT mice. $P< 0.05, HP diet vs. control diet in GPRC6A mice determined
using multiple t test. n5 6–7 per group.
Figure 4 Relative expression of GPRC6a mRNA in different regions of the gastroin-
testinal tract of mice fed either a control or high-protein (HP) diet for 5 weeks, and
then fasted overnight. GPRC6a mRNA expression is shown as expression relative
to control diet. Data is presented as mean6SEM. n5 7.
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Discussion
GPRC6A can act as a nutrient sensing receptor detecting L-amino
acids and has been suggested to regulate energy homeostasis in
response to protein intake. As such it has been proposed as a putative
target for antiobesity agents (13,31). Our data demonstrates that while
GPRC6A is expressed throughout the murine gastrointestinal tract, it
is not necessary for the effects of low- or high-protein diets on energy
homeostasis in mice. GPRC6a ablation had no impact on the effects of
low- or high-protein diets in mice. We observed reductions in food
intake and body weight in both WT and GPRC6a-knockout mice
when animals were placed on low- or high-protein diets.
Rodents typically exhibit a reduction in body weight and food intake
when placed on a high-protein diet (29). In rats, consumption of a
high-protein diet for several days reduces cumulative food intake,
weight gain, and adiposity compared to a normal-protein diet control
(32). Two different GPRC6a knockout models have been generated
to investigate the molecular signaling and physiological role of the
receptor (13). These knockout models were generated by two differ-
ent molecular approaches which consisted of partial deletion of
GPRC6a exonic regions coding either the receptor seven transmem-
brane region (15) or part of the ligand binding site (14). Although
Pi et al. reported differences in basal blood glucose levels and
response to an IPGTT in their GPRC6aexon 2(2/2) model (14), Smaji-
lovic et al. observed no differences in basal blood glucose levels or
in the response to an oral GTT in their GPRC6aexon 6(2/2)model
(16). We found no differences in basal glucose levels or in the
response to an IPGTT between WT and our GPRC6a-KO model, in
accord with the phenotype of the GPRC6aexon 6(2/2) model. While
discrepancies in the phenotypes of these models have been reported,
data from both suggests a possible role for GPRC6A in energy
homeostasis (14,17). The GPRC6A knockout model used in present
studies has the entire GPRC6a gene deleted. These studies therefore
demonstrate that GPRC6A is not necessary for the effects of low- or
high-protein diets on body weight.
The length of exposure to diets with altered protein content can
influence the effects observed. We subjected mice to 9 and 35 days
of low- or high-protein diets, respectively. However, it is possible
that a longer exposure might have revealed differences between the
cohorts. For example, a recent study investigating mice lacking
GPRC6a found they required exposure to a high-fat diet for over 4
months to demonstrate a significant difference in body weight com-
pared to WT controls, and only detected differences in percentage
body fat after 25 weeks (17).
Mice generally lose weight when initially exposed to low-protein diets
(30). In our WT mice, this effect did not achieve statistical signifi-
cance. Previous rodent studies have also demonstrated an increased
food intake and body fat associated with moderately low levels of die-
tary protein (5,6). The ratio of macronutrients and amino acids in the
diet can also modulate energy homeostasis. For example, a recent
study suggests that increased circulating levels of hepatic fibroblast
growth factor 21 (FGF21) function as a specific endocrine signal of
protein restriction in rodents, and mediate behavioral and metabolic
responses to protein restriction (33). The altered amino acid content in
our experimental diet may therefore have had subtle effects on energy
homeostasis that were not detected in our studies, and which may have
differed between GPRC6a knockout and WT mice.
There may be multiple overlapping systems mediating the effects of
dietary amino acids and proteins on food intake (2). The deletion of a
single receptor, such as GPRC6A, may not therefore be sufficient to
prevent the effects of altered dietary protein content on food intake.
The T1R1/T1R3 receptor heterodimer and the CaSR have also been
suggested to be involved in amino acid sensing in the gut. Recent
studies suggest T1R1/T1R3 may act as a sensor of amino acid avail-
ability that regulates the activity of the mammalian target of rapamy-
cin (34). Specific L-amino acids can stimulate anorectic gut hormone
release from isolated I-cells and rat small intestine through a CaSR-
Figure 5 The effect of a low-protein diet (LP) on (A, B) body weight gain and (C)
cumulative food intake in male WT and GPRC6a-KO mice. Data is presented as
mean6SEM. *P< 0.05 vs. LP diet group determined using generalized estimating
equation curve analysis for the entire 9 days. n57–8 per group.
Obesity GPRC6A in Protein Sensing and Energy Balance Kinsey-Jones et al.
1198 Obesity | VOLUME 23 | NUMBER 6 | JUNE 2015 www.obesityjournal.org
dependent mechanism (35,36). Furthermore, a recent study has dem-
onstrated that GPRC6A is involved in L-amino acid-induced GLP-1
secretion from the GLUTag enteroendocrine cell line (31). Deletion
of GPRC6a did not result in compensatory changes in expression of
the other two promiscuous L-amino acid receptors in the gastrointesti-
nal tract, though it is possible that the activity of these receptors may
be altered by, for example, altering their localization to the cell mem-
brane. In addition, exposure to a high-protein diet for 5 weeks seemed
to have no effect on the expression of GPRC6a in gastrointestinal
tract (Figure 4). However, it is possible that there were changes in
GPRC6A protein concentrations, even though we detected no signifi-
cant change in GPRC6a mRNA expression. Further studies investi-
gating this possibility will require the use of antibodies with demon-
strated specificity for GPRC6A.
Alternatively, other protein sensing mechanisms may compensate
for the absence of GPRC6A. GPR93, a G-protein coupled receptor
of the family A, is highly expressed on cholecystokinin (CCK)
releasing I cells in small intestine, and has been implicated in the
sensing of protein hydrolysate in the gastrointestinal lumen (37).
Peptone stimulates the release of CCK from STC-1 cells via a
GPR93 dependent mechanism (38). Mu-opioid receptors (MOR)
have recently been demonstrated to play a role in protein sensing.
MORs in neurons in the portal vein walls sense peptides in the
blood which are released into the portal circulation following inges-
tion of a high-protein meal. These peptides antagonise MORs, regu-
lating a gut-brain neural circuit that ultimately controls satiety and
food intake (39). Amino acid transporter systems may also be impli-
cated in protein sensing. Evidence suggests that in addition to their
transport role, amino acid transporters have receptor-like properties,
regulating nutrient induced signalling by sensing cellular amino acid
sufficiency. For example, the sodium-coupled neutral amino acid
transporter 2 (SNAT2) has shown to have transceptor activity and
been implicated in glutamine-stimulated GLP-1 release from intesti-
nal L-cells (40). We used cooked chicken breast as a model of high-
protein food in our acute high-protein study (Figure 2) and observed
an acute reduction in food intake in mice orally gavaged with
chicken breast compared to water control. Although different protein
loads may have different chronic effects on food intake and body
weight, acute satiating effects can be difficult to detect in mice, and
therefore require large cohorts of animals to investigate. Although
water does not control for the differences in energy intake, it was
used in our acute study to control for the initial changes in stomach
distention caused by administration of the homogenised chicken
breast.
The expression of GPRC6A in the gut, its activation by L-amino
acids, and its putative ability to mediate hormone release has sug-
gested that GPRC6A is a promising candidate for mediating the ano-
rectic effects of altered dietary protein. However, our studies suggest
that GPRC6A does not play a critical role in protein-mediated
changes in appetite and body weight and thus may not be involved
in protein sensing in the gut.O
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